Main Article Content
Background. Increase of morbidity of diabetes mellitus (DM) associated with coronary artery disease (CAD) on the background of metabolic syndrome (MS) is worrisome. It is very important to improve the diagnosis of this associated pathology and also to develop pathogenetic therapy, taking into account the specific stage of disease. The purpose of our work was to study the correlation of compensated and decompensated type 2 DM on the background of MS with chronic CAD. Materials and methods. 231 patients with MS and with or without type 2 DM and chronic CAD were examined. MS was characterized by the II–IIІ degree of obesity in all studied groups. The levels of cortisol, prolactin, free thyroxine, thyroidstimulating hormone (TSH), lipids were evaluated in all patients, ultrasonography of the heart was performed. Results. Increase of cortisol levels, prolactin in women, TSH, change of lipids as high levels of triglycerides, very lowdensity lipoprotein cholesterol, at the control value of highdensity lipoprotein cholesterol, lowdensity lipoprotein cholesterol and total cholesterol was detected in patients with metabolic syndrome, and also patients with compensated type 2 DM on the background of MS. Increase of interventricular septal thickness and left atrium anteroposterior dimension was observed in patients of this group. Increased levels of cortisol and prolactin as well as the control level of TSH were detected in patients with MS and decompensated type 2 DM as well as with or without chronic CAD. Increase of interventricular septal thickness, left ventricular posterior wall thickness, left atrium anteroposterior dimension was observed in patients of both groups according to results of ultrasonography. High level of total cholesterol, lowdensity lipoprotein cholesterol, triglycerides, very lowdensity lipoprotein cholesterol and low level of highdensity lipoprotein cholesterol were observed in patients with MS and decompensated type 2 DM associated with chronic CAD compared to patients with MS and type 2 DM without chronic CAD. Conclusions. The pathogenetic and clinical relation of type 2 DM was established in MS and chronic CAD.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Smilowitz NR, Gupta N, Guo Y, Beckman JA, Bangalore S, Berger JS. Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart. 2018 Jul;104(14):1180-1186. doi: 10.1136/heartjnl-2017-312391.
van Herpt W, Dehghan A, Hoek M, et al. The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study. Cardiovasc Diabetol. 2016 Apr 27;15:69. doi: 10.1186/s12933-016-0387-4.
De Santis AS, Diez Roux AV, Hajat A, et al. Associations of Salivary Cortisol Levels with Metabolic Syndrome and Its Components: The Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab. 2011 Nov;96(11):3483-92. doi: 10.1210/jc.2011-0483.
Incollingo Rodriguez AC, Epel ES, White ML, Standen EC, Seckl JR, Tomiyama AJ. Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: a systematic review. Psychoneuroendocrinology. 2015 Dec;62:301-18. doi: 10.1016/j.psyneuen.2015.08.014.
Mahbuba S, Mohsin F, Rahat F, Nahar J, Begum T, Nahar N. Descriptive epidemiology of metabolic syndrome among obese adolescent population. Diabetes Metab Syndr. 2018 May;12(3):369-374. doi: 10.1016/j.dsx.2017.12.026.
Gundogan K, Bayram F, Gedik V, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci. 2013 Apr 20;9(2):243-53. doi: 10.5114/aoms.2013.34560.
Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohortstudy. Eur Heart J. 2015 Mar 1;36(9):551-9. doi: 10.1093/eurheartj/ehu123.
van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014 Feb 1;14:9. doi: 10.1186/1472-6823-14-9.
International Diabetes Federation Epidemiology Task Force Consensus Group. The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html.
Libo Y, Xiaohong L, Feng Y, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of metabolic syndrome: A meta-analysis of observational studies. Endocr Res. 2016 May;41(2):158-65. doi: 10.3109/07435800.2015.1108332.
Velarde GP, Sherazi С, Cremer DF, et al. Clinical and Biochemical Markers of Cardiovascular Structure and Function in Women With the Metabolic Syndrome. Am J Cardiol. 2015 Dec 1;116(11):1705-10. doi: 10.1016/j.amjcard.2015.09.010.